Floatz logo

Lestaurtinib

Leukemia

Children's Oncology GroupSmall moleculePhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Lestaurtinib is also rated in:

T-cell childhood acute lymphocytic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →
acute undifferentiated leukemiaDormant
B
Indicative ·
62 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →